BiotechTube
Broadwing Bio

Broadwing Bio

Cambridge, United States· Est.
broadwing.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Broadwing Bio is a private, pre-clinical stage biotech developing antibody therapies for Geographic Atrophy and Glaucoma, two leading causes of irreversible blindness with significant unmet need. The company leverages a genetics-centric discovery platform, building on insights from human genetic variants, and utilizes the antibody generation capabilities of its strategic partner, Alloy Therapeutics. Founded by veterans from Genentech and Calico, Broadwing is assembling a team with deep drug discovery expertise to advance its mission of ending blindness.

OphthalmologyRetinal DiseasesNeurodegenerative Eye Disease

Technology Platform

Genetics-driven antibody discovery platform leveraging human genetic variants that confer protection against ocular diseases, partnered with Alloy Therapeutics for antibody generation capabilities.

Opportunities

The recent validation of the GA market with first-ever drug approvals opens a multi-billion dollar opportunity for improved therapies.
In glaucoma, a neuroprotective treatment would be a paradigm shift in a large, established market.
The genetics-first approach could lead to high-value, first-in-class assets attractive for partnership or acquisition.

Risk Factors

High scientific risk in translating genetic insights into effective drugs in a highly competitive ophthalmology landscape.
Heavy reliance on early pipeline success and future venture financing in uncertain markets.
Execution risk in managing key partnerships and building internal capabilities.

Competitive Landscape

The GA space is now competitive with approved complement inhibitors (Apellis, Iveric Bio/Astellas) and many others in development. Glaucoma is dominated by IOP-lowering drugs from companies like Novartis, Allergan, and newer entrants. Broadwing's differentiation hinges on its novel, genetically validated targets, but it will face competition from large pharma and biotechs with greater resources.

More companies in Biologics / Biosimilars →More companies in United States →